Abstract:
The present invention relates to a composition for treating or preventing inflammatory diseases. The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, which comprises a Myagropsis myagroides extract or a fraction of the extract as an active ingredient. The Myagropsis myagroides extract or the fraction thereof does not contain known existing fucoxanthin but controls the generation of nitrogen monoxide (NO), prostaglandin E_2 (PGE_2) and inflammatory cytokines and also controls the expression of iNOS and COX-2 effectively so that the pharmaceutical composition can be used usefully for preventing and treating inflammatory diseases. [Reference numerals] (AA) Myagropsis myagroides; (BB) Sun drying; (CC) Extraction by reflux condensing (Repeat three times); (DD) Powder; (EE) Extract; (FF) Vaccum filtration; (GG) Vacuum rotating concentration/40°C (solvent removal); (HH) Crude extract; (II) Myagropsis myagroides crude extract; (JJ) Organic solvent soluble fractioning (Repeat 3-4 times); (KK) n-hexane soluble fraction; (LL,NN,PP,RR) Water soluble fraction; (MM) Dichloromethane soluble fraction; (OO) Ethyl acetate soluble fraction; (QQ) n-butanol soluble fraction
Abstract:
PURPOSE: A composition containing Ecklonia stolonifera or Ecklonia cava spirit extract is provided to suppress tyrosinase expression and melanogenesis. CONSTITUTION: A composition with a whitening effect contains Ecklonia stolonifera spirit extract as an active ingredient. The Ecklonia stolonifera spirit extract is used as a material for a cosmetic product for skin whitening, a pharmaceutical product for treating hyperpigmentary dermatitis, and a functional food for whitening. The composition also contains Ecklonia cava spirit extract as an active ingredient. The composition additionally contains dieckol or phlorofucofuroeckol A as an active ingredient. [Reference numerals] (AA) Ecklonia stolonifera/Ecklonia cava; (BB) Drying in the shade; (CC) Powder; (DD) - reflux condensing extraction(repeat three times) - using spirit; (EE) Extraction; (FF) Filtering by reduced pressure; (GG) - vacuum rotary concentration - 40°C(removing organic solvent); (HH) Ecklonia stolonifera/Ecklonia cava crude extract; (II) Organic solvent soluble fraction(repeat 3-4 times); (JJ) N-hexane soluble extract; (KK) Water soluble fraction; (LL) Dichloromethane soluble extract; (MM) Water soluble fraction; (NN) Ethyl acetate soluble extract; (OO) Water soluble fraction
Abstract:
본 발명은 다시마의 물 또는 유기용매 바람직하기는 에탄올, 주정 및 아세톤 추출물과 에탄올 추출물로부터 분획한 n-헥산 그리고 그의 디클로로메탄 분획물이 염증매개인자인 iNOS와 COX-2 발현을 억제하고 이 효소에 의해 생성되는 NO와 proinflammatory cytokine의 생성억제에 효과적인 것을 확인하여 염증 관련 질병의 예방 및 치료에 유용한 유효성분을 함유한 것을 특징으로 하는 항염증 약학조성물을 개시한다.
Abstract:
본 발명은 곰피 또는 감태 주정 추출물로부터 분리된 플로로탄닌류를 함유하는 알콜성 간손상에 대한 간보호용 조성물에 관한 것으로, 보다 구체적으로는 곰피 또는 감태 주정 추출물에 함유된 플로로탄닌류가 알콜에 의한 HepG2 간세포 손상에 대하여 간세포 사멸 억제효과를 갖는 간 보호용 조성물에 관한 것이다.
Abstract:
PURPOSE: A Laminaria japonica-derived composition for whitening is provided to suppress melanogenesis in melanoma cells and to be used in a functional cosmetic product, functional food, or pharmaceutical composition for whitening. CONSTITUTION: A cosmetic composition for skin whitening contains Laminaria japonica spirit extract, n-hexane soluble extract, or dichloromethane soluble extract as an active ingredient. A pharmaceutical composition for treating pigmentary disorders contains the Laminaria japonica spirit extract, n-hexane soluble extract, or dichloromethane soluble extract as an active ingredient.
Abstract:
PURPOSE: A hepatoprotection composition containing phlorotannins isolated from Ecklonia stolonifera or Ecklonia cava extract is provided to be used as a pharmaceutical composition for preventing and treating liver diseases. CONSTITUTION: A hepatoprotection composition which suppresses hepatocyte injury due to alcohol contains spirit extract of Ecklonia stolonifera or Ecklonia cava as an active ingredient. A health food composition for hepatoprotection contains the spirit extract of Ecklonia stolonifera or Ecklonia cava as an active ingredient. A pharmaceutical composition for hepatoprotection contains phlorotannin compounds as an active ingredient, isolated and purified from an ethyl acetate fraction of Ecklonia stolonifera or Ecklonia cava. The phlorotannin compounds are eckol, dieckol, dioxynodehydroeckol, phlorofucofuroeckol A, and phlorofucofuroeckol B. [Reference numerals] (AA) Ecklonia stolonifera and Ecklonia cava; (BB) Shade drying; (CC) Powder; (DD) Reflux extraction(repeat three times), using spirit; (EE) Extraction; (FF) Filtering at reduced pressure; (GG) Vacuum concentration, 40°C(removing organic solvent); (HH) Crude extract of Ecklonia stolonifera and Ecklonia cava; (II) Organic solvent soluble fraction(repeat 3-4 times); (JJ) N-hexane soluble extract; (KK) Water soluble fraction; (LL) Dichloromethane soluble extract; (MM) Water soluble fraction; (NN) Ethyl acetate soluble extract; (OO) Water soluble fraction